Supreme Court Questions Standing in Abortion Pill Case

The U.S. Supreme Court has raised questions regarding the legal standing of doctors and anti-abortion groups challenging the FDA’s label for the commonly used abortion pill mifepristone. At issue is whether these respondents have suffered any harm due to significant label changes in 2016 and 2021 which made the pill accessible by mail and extended its use in pregnancy by three weeks.

WuXi Bio Highlights Client Relationships Amid Uncertainty

Service provider WuXi Biologics outlines its almost 700 pipeline projects in its annual report, showing a strong client relationship focus. Despite stock challenges for WuXi and sister company WuXi AppTec, CEO Chris Chen remains confident about the company’s strategy and future commercial manufacturing deals.

Pfizer Ends One of Two Late-Stage Trials for Sickle Cell Drug

Pfizer has terminated one of its Phase 3 trials for a sickle cell treatment candidate due to poor accrual, although another is continuing. Despite the setback, the pharmaceutical giant still plans to seek BLA approval for the treatment in 2026.

Eversana and MyHealthTeam Partner

Healthcare company Eversana and patient social network MyHealthTeam have partnered to help faster diagnose and treat patients. The collaboration aims to streamline the process, eliminating any disruptive treatment delays and speeding up the entire process from symptoms to treatment.

Shortage of Eli Lilly Insulins Expected Until April

Pharmaceutical company Eli Lilly has warned that two of its insulin products will face a shortage until the early part of April. The firm didn’t specify the cause but is in continuous contact with the FDA and manufacturing to address the issue promptly.

Astellas’ Gastric Cancer Drug Approved in Japan

Astellas’ gastric cancer drug, Vyloy, has won approval in Japan after being rejected by the FDA earlier this year. Vyloy, which targets a protein expressed on the surface of gastric cancer cells, is the first of its kind to receive worldwide approval.